Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **large intestine microbiota**, also known as colonic or gut microbiota when referring specifically to this region, comprises trillions of microorganisms—including bacteria (~1000+ species), archaea, viruses/phages/fungi—that inhabit the human colon. This diverse ecosystem plays essential roles in digestion by fermenting otherwise indigestible dietary fibers into short-chain fatty acids that nourish colonocytes and influence systemic metabolism. It synthesizes vitamins unavailable from diet alone; regulates local/systemic immunity; protects against pathogen overgrowth; maintains mucosal barrier integrity; interacts bidirectionally with other organs including via neuroimmune pathways (“gut-brain axis”). Disruption or imbalance (“dysbiosis”) has been linked to numerous diseases ranging from metabolic syndrome/obesity/type II diabetes/inflammatory bowel disease/neuropsychiatric conditions/cancer/cardiovascular risks. Therapeutic strategies focus on restoring healthy balance through diet modification/prebiotic supplementation/probiotic administration/fecal transplantation rather than targeting any one molecule within this system directly.[1][3][4]
For interventions:\n - Modulation/restoration/correction of dysbiotic communities by introducing beneficial microbes/providing substrates for their growth/providing competitive exclusion against pathogens/influencing metabolite production such as SCFAs/regulating immune signaling pathways/gut-brain axis modulation through metabolites/neuroactive compounds produced by microbes[2].
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Large intestine microbiota (None established; sometimes referred to as "gut microbiota" or "intestinal microbiota," but no standard abbreviation specific to the large intestine.).